Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executives On The Move: New Arrivals In Commercial For Exopharm And Primex, And A Departure At Grupo Biotoscana

Executive Summary

For Exopharm, an Australian regenerative medicine firm, a new chief commercial officer, and for Primex Pharmaceuticals, a global anesthesia products company, a new head, global commercial. Over at Latin American advanced medicines business Grupo Biotoscana, a CEO resignation.

You may also be interested in...



Executives On The Move: Comings And Goings At JSC Olainfarm And MorphoSys, Plus A Promotion At Twist Bioscience

Latvian pharma producer JSC Olainfarm picks next CEO and chairman, and CSO is scheduled to depart German therapeutic antibody company MorphoSys. Meanwhile, synthetic DNA manufacturer Twist Bioscience promotes SVP to chief commercial officer.

Executives On The Move: A Finance And Development Change At EyePoint Pharma And Exits At PPD And Novartis

Ophthalmology biopharma EyePoint Pharmaceuticals confirms its new CFO and head of corporate development. A former PPD med director is now CMO of vaccine developer ILiAD Biotechnologies and neurological disorders firm Ovid Therapeutics adds ex-Novartis VP as chief commercial officer.

Executives On The Move: Teva Pharma Picks A CFO, Ipsen Decides On An R&D Position And Bavarian Nordic Names Its Commercial Hire

Teva Pharmaceuticals now has a new EVP, CFO. Ipsen Group decides on a former Shire Pharma CMO for Head, R&D and Bavarian Nordic names a vaccines commercial leader from GSK to be Chief Commercial Officer in 2020.

Topics

UsernamePublicRestriction

Register

SC126157

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel